使用FAERS数据库评估SSRI/SNRIs出血风险的科学方法
Xiaodan Zhou1, Shixin Xiang1, Bangtian Xu1
1Department of Pharmacy, University-Town Hospital of Chongqing Medical University, Chongqing, China.
Psychiatry research
|February 9, 2025
概括
选择性血红素再吸收抑制剂 (SSRI) 和血红素-上腺素再吸收抑制剂 (SNRIs) 与与出血相关的不良事件 (HrAEs) 有关. 这项研究将胃肠道和神经系统疾病确定为主要关注点,特定的抗抑郁药物显示出显著的关联.
科学领域:
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
- 药品安全 药品安全
背景情况:
- 出血是一种与选择性色素再吸收抑制剂 (SSRI) 和色素 - 上腺素再吸收抑制剂 (SNRIs) 相关的显著不良事件 (AE).
- 了解这些出血事件对于告知临床实践和确保患者安全至关重要.
研究的目的:
- 综合分析与SSRI和SNRI相关的出血事件.
- 为了解这些不良事件的临床影响提供见解.
主要方法:
- 利用主要SSRI/SNRIs的FAERS数据库中的十年数据 (2014-2023年).
- 员工报告概率率 (ROR) 和比例报告率 (PRR) 用于信号量化.
- 对人口统计数据,结果和药物相关性进行了比较分析.
主要成果:
- 与出血相关的AE (HrAEs) 约占所有SSRI/SNRIAE的3.86%,主要影响60岁以上的女性.
- 胃肠道和神经系统疾病是出血的主要积极信号 (p-HrAEs).
- 塞特拉林显示出强烈的信号,对上部胃肠道出血; 奇塔洛普拉姆, 埃斯基塔洛普拉姆, 帕洛克塞丁和文拉法辛与大脑/小脑血瘤有关.
结论:
- 药监测分析确定了与SSRI/SNRIs相关的p-HrAEs.
- 这些发现有助于更好地了解安全和合理的抗抑郁药物使用.
相关概念视频
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
285
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
285
Antidepressant Drugs: MAOIs and Other Agents
183
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
183
Hazard Ratio
78
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
78
Relative Risk
111
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
111
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
114
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
114
SBAR II: Application of SBAR
4.3K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.3K


